Biomet announced Tuesday that it has purchased Cartilix, based out of Foster City, Ca.
Cartilix is a company that has developed proprietary cartilage repair technology.
It was founded in 2004 to develop cartilage repair and regeneration solutions.One item Cartilix developed is ChonDuxtm,, a propietary cartilage regeneration technology for repair of knee cartilage. It uses a biological adhesive and hydrogel to fill articular cartilage lesions.
The technology is not yet commercially available. Clinical trials are scheduled to begin in Europe sometime in the first half of 2010.
A U.S. clinical trial is expected to follow soon after.
"We believe that Cartilix's technology platform is a great fit for Biomet's continuum of solutions for knee disorders," said Jeff Binder, Biomet President and CEO. "Biomet has a rapidly growing sports medicine franchise, the world's leading partial knee replacement system and the most comprehensive total knee replacement system on the market, allowing us to provide a broad spectrum of solutions for varying degrees of knee disorders. The Cartilix technology provides Biomet with an opportunity to facilitate earlier intervention in pre-arthritic patients."
